| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In the latest quarter, 6 analysts provided ratings for Inspire Medical Systems (NYSE:INSP), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $250.83, a high estimate of $285.00, and a low estimate of $185.00. Witnessing a positive shift, the current average has risen by 3.79% from the previous average price target of $241.67.
The perception of Inspire Medical Systems by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Bob Hopkins | B of A Securities | Lowers | Neutral | $185.00 | $225.00 |
| Adam Maeder | Piper Sandler | Raises | Overweight | $255.00 | $250.00 |
| Shagun Singh | RBC Capital | Announces | Outperform | $285.00 | - |
| Anthony Petrone | Mizuho | Maintains | Buy | $250.00 | $250.00 |
| Richard Newitter | Truist Securities | Maintains | Buy | $280.00 | - |
| Kallum Titchmarsh | Morgan Stanley | Announces | Overweight | $250.00 | - |
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Inspire Medical Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Inspire Medical Systems analyst ratings.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Inspire Medical Systems's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 28.24%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inspire Medical Systems's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Inspire Medical Systems's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.72%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Inspire Medical Systems's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.47%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INSP
